Navigation Links
NuvaRing Lawsuit Filed by Alonso Krangle on Behalf of a Louisiana Woman Who Developed Pulmonary Embolism Allegedly Due to NuvaRing Use
Date:7/28/2013

New York, NY (PRWEB) July 28, 2013

Alonso Krangle’s attorneys have recently filed a NuvaRing lawsuit against Organon, Merck and others on behalf of a woman from Louisiana. This case (Case No. 2:13-cv-03678-SDW-MCA) was filed June 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc., N.V. Organon, the Schering Corporation, Merck & Co., Inc., and Merck Sharp & Dohme.

In addition to alleging that use of NuvaRing caused the plaintiff to develop a serious lung condition known as pulmonary embolism, this case alleges that Organon and the other defendants knew but failed to publicly disclose the fact that NuvaRing had a higher risk of blood clot-related complications than oral contraceptives. Furthermore, this NuvaRing lawsuit contends that Organon and the other defendants failed to adequately safety test NuvaRing and negligently marketed NuvaRing as a safe and effective birth control medication without warning consumers about the potential risks of serious NuvaRing side effects.

Alonso Krangle’s experienced NuvaRing lawsuit attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

According to court documents in this NuvaRing lawsuit, the plaintiff began using NuvaRing in December 2006. After developing chest pain, coughing and shortness of breath, in July 2012, she sought medical attention and underwent a CT scan, at which time she was informed that she had developed multiple pulmonary emboli. Pulmonary emboli are blood clots lodged in the lungs that can severely impair breathing and result in life-threatening complications. Following this diagnosis, the plaintiff was hospitalized for two days, was advised to stop using NuvaRing and was placed under anticoagulation therapy, including Lovenox and Coumadin. While the plaintiff had to continue her anticoagulation therapy after being released from the hospital, she has also had to undergo regular follow-up care to monitor her health.

Risk of Serious Complications Associated with NuvaRing Use

The link between NuvaRing use and the development of serious blood clot disorders like pulmonary embolism has been reported by many medical researchers within recent years. In fact, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots, when compared to the risk associated with older birth control pills.
( nejm.org/doi/full/10.1056/NEJMoa1111840 )

Another study published in May 2012 in the British Medical Journal found that women’s risk of developing blood clots increased at least 6.5 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
( bmj.com/content/344/bmj.e2990#alternate )

Seeming to support the alleged link between NuvaRing use and serious blood clots is information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects patients reported after NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, upwards of 30 percent of women who reported NuvaRing complications required hospitalization, and approximately 3 percent of NuvaRing complications resulted in death.
( adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING )

About Alonso Krangle LLP And Filing A NuvaRing Lawsuit

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have dedicated their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is offering FREE NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact 1-800-403-6191 or visit the website, FightForVictims.com. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10963121.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
2. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
3. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
4. NuvaRing Blood-Clotting Victims Still Eligible to File Lawsuits Through Resource4thePeople
5. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
6. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
7. NuvaRing Blood-Clotting Claims Now Being Investigated by Resource4thePeople Attorneys
8. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
9. 2013 NuvaRing Blood-Clotting Allegations Inquiries Eligible for Review by Resource4thePeople Attorneys
10. Rescheduling of First NuvaRing Lawsuit Trials in State, Federal NuvaRing Lawsuit Litigation, Reports Wright & Schulte LLC
11. First NuvaRing Lawsuits in State, Federal NuvaRing Litigations Set to Head to Trial Later This Year, Alonso Krangle LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , developer of ... Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South Africa. ... incentives to a patient’s remote health progress, empowering the patient to take direct responsibility ...
(Date:4/26/2017)... ... ... Infertility may be a result of an underlying pelvic ... become pregnant upon treating their diagnosis. , To properly diagnose patients, ... can provide the necessary information to diagnose and treat your problem. , ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn ... ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology is a ... food, with fewer resources. It highlights the business’ principles, research and collaboration efforts ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a ... announce that it has received 510(k) clearance from the U.S. Food & Drug ... MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Medicine Technology: